FCGR3A and acute myeloid leukemia: Moreover, a TriKE to target acute myeloid leukemia (AML) was developed to contain a humanized anti-CD16 heavy chain camelid single-domain antibody, which activates NK cells, an IL-15 molecule that drives NK-cell expansion and survival, and an scFv against human CLEC12A that is highly expressed in AML [197].